Brief: Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met

Grail

19/02/2026 21:36

Feb 19 (Reuters) - Grail Inc GRAL.O:

LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES, INCREASED STAGE I AND II DETECTION OF DEADLY CANCERS, AND FOUR-FOLD HIGHER CANCER DETECTION RATE

GRAIL INC: PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT COMBINED STAGE III-IV REDUCTION WAS NOT MET

GRAIL INC: PLANS TO EXTEND TRIAL'S FOLLOW UP PERIOD BY 6-12 MONTHS

Source text: ID:nPn7ylVKDa

Further company coverage: GRAL.O

 ((Reuters.Briefs@thomsonreuters.com;))